Patent ID: 7351875
Filing Date: 2008-04-01
Classification: A01K,A61P,C07K,C12N

Abstract:
1. A method for screening a compound that is able to suppress aberrant immune activity, wherein the aberrant immune activity is selected from aberrant immune complex formation, aberrant immune complex clearance and immune complex induced inflammation, the method comprising the steps of: a. administering a compound to be screened to transgenic mouse generated by transgenically modifying an embryo from a strain, derived from strains C57BL/6 and SJL, that is resistant to collagen-induced arthritis, such that said mouse comprises and expresses a transgene for human FcγRIIa receptor, whereby the expression of said FcγRIIa renders the mouse susceptible to an autoimmune disease caused by aberrant immune complex formation, aberrant immune complex clearance or immune complex induced inflammation; and b. assessing the transgenic mouse to determine if the compound reduces aberrant immune activity in the mouse; wherein said autoimmune disease is selected from the group consisting of arthritis and systemic lupus erythematosus.